Caplin Point Laboratories Limited Business Intelligence Report
Caplin Point Laboratories Limited Business Intelligence Report
Quality Scores
Latest Quarterly Earnings Summary
Loading latest quarter…
AI Summary
Caplin Point Laboratories (CPL) is a rare niche-focused pharmaceutical player that has successfully transitioned from a trading-led model in Latin America (LatAm) to a vertically integrated manufacturer with a growing US FDA footprint. Over the last decade, the company has maintained remarkable capital efficiency (ROCE > 25%) while scaling revenue at 25% CAGR. It dominates underserved markets like LatAm and francophone Africa, where it enjoys high margins due to unique distribution and a vast portfolio of 4,000+ licenses. The recent pivot towards 'Caplin Steriles' targeting the US market…
Key Changes in FY2026
The company has undergone a significant transformation from a merchant exporter to an integrated pharmaceutical enterprise with manufacturing and R&D capabilities. Initially focused on distributive models in LatAm and Africa, Caplin Point has successfully pivoted towards regulated markets including the USA. The portfolio has expanded to over 4,000 registered licenses and 650 formulations, covering more than 65% of the WHO essential drug list. Digital transformation is evident in their logistics and supply chain management within niche Latin American markets, creating a logistical moat. The entry into complex injectables and oncology signals a move up the value chain into high-margin segments. This evolution is reflected in the ROE/ROCE remaining consistently above 20% despite heavy R&D…
Management Commentary
Promoter holding is stable and high at ~70.5%, indicating significant skin in the game. Management communication is transparent through regular quarterly earnings calls and detailed presentations. The founder’s vision of focusing on 'bottom of the pyramid' markets has built a wide moat that larger pharmaceutical companies struggle to penetre. While the leadership transition to the next generation is underway, the focus on R&D (650 formulations) suggests a forward-looking approach. There are no major historical instances of governance lapses or frequent changes in key management personnel.
Financial Highlights
CPL has delivered consistent top-line growth, scaling from ₹252 Cr in FY15 to ₹2,187 Cr in FY26 (projected/TTM), representing a 22-25% CAGR. Operating profit margins have remained robust between 30-36%, a testament to its pricing power in frontier markets. Net profit has grown at 30% CAGR over 10 years, outstripping sales growth and showcasing operational leverage. However, recent trends show a slight compression in margins as the company invests in R&D and US compliance. The balance sheet is exemplary, with minimal debt and total equity growing from ₹93 Cr to over ₹3,500 Cr in the decade studied.
Major Opportunities
- Consistent 30% 10-year PAT CAGR
- Zero net debt status
- Strong OPM consistently >30%
Major Risks
- Significant increase in Cash Conversion Cycle
- Debtor days risen from 8 to 138 over 10 years
- Inventory days peaked at 210 in 2020
About Caplin Point Laboratories Limited's Annual Report & Financial Performance
The latest Caplin Point Laboratories Limited annual report (FY2026) is the company's flagship annual disclosure, filed with NSE / BSE. It covers the full-year business review, management discussion & analysis, audited financial statements, the director's report, the corporate governance and auditor's reports, risk factors, capital allocation, subsidiaries, related-party transactions and ESG initiatives. This Business Intelligence Hub consolidates the official filings with AI-generated financial analysis so investors can see how revenue, operating margin, cash flow quality, capex, dividends, net debt and management outlook have changed — without reading the entire filing.
What this Caplin Point Laboratories Limited research covers
- Fundamental & business analysis
- Financial statements & performance
- Management commentary & discussion
- Corporate governance & auditor report
- Cash flow analysis & capital allocation
- Valuation analysis & business quality
- Growth analysis & competitive position
- Risk, SWOT & moat analysis
- Quarterly earnings & conference-call summary
- Sector, industry & peer comparison
- Latest official company filings
- Business outlook & long-term growth
Caplin Point Laboratories Limited — Frequently Asked Questions
Explore more Caplin Point Laboratories Limited research
AI Top Insights — Premium
Unlock deeper AI Top Insights, advanced comparisons, downloadable reports and premium features.